ST-Humanwell (600079.SH) has announced that its majority-owned subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), recently disclosed the Phase II clinical trial registration information for RFUS-188 injection on the National Medical Products Administration's drug clinical trial registration and information disclosure platform.

The trial is designed as a multicenter, randomized, double-blind, parallel, placebo/active-controlled, two-stage study to evaluate the efficacy and safety of RFUS-188 injection for postoperative analgesia following abdominal surgery. The primary objectives are twofold: first, to explore the effective dose of RFUS-188 injection for postoperative pain management in Part A; second, to assess the efficacy and safety of the drug in Part B. A secondary objective involves investigating the pharmacokinetic and pharmacodynamic characteristics of repeated RFUS-188 injection dosing for postoperative analgesia.